Top Markets
Coin of the day
Mydecine Innovations Group Inc. Mydecine Innovations Group Inc.

Mydecine Innovations Group Inc.

MYCO
株式のランク #30738
Mydecine Innovations Group Inc. is a biotechnology and life sciences enterprise... Mydecine Innovations Group Inc. is a biotechnology and life sciences enterprise dedicated to advancing and commercializing therapies for a range of mental health conditions. The company specializes in developing treatments for specific populations, including veterans, emergency medical service providers, frontline workers, and individuals affected by post-traumatic stress disorder. It also operates Mindleap, an online telehealth platform offering mental wellness services and support for psychedelic integration, including aftercare. Furthermore, Mydecine engages in drug discovery, developing nature-derived psychedelic-assisted therapeutics, novel compounds, specific therapy protocols, and unique drug delivery systems. The company also manages a hemp cultivation facility in Pottus, Texas. Strategic collaborations include alliances with Leiden University Medical Center, Royal Ottawa Mental Health Centre, and LeadGen Labs for psychedelic drug development, as well as Applied Pharmaceutical Innovation for drug development and clinical trial programs. Founded in 2013, the company, originally known as NewLeaf Brands Inc., rebranded as Mydecine Innovations Group Inc. in June 2020 and is headquartered in Vancouver, Canada.
株価
$0.25687791
最終同期: 2026-01-13
時価総額
$15.72M
変化(1日)
100.54%
変化(1年)
6,975.98%
CA
取引 Mydecine Innovations Group Inc. (MYCO)

カテゴリー

Mydecine Innovations Group Inc.(MYCO)の営業利益率
2026 時点の営業利益率 TTM: 0.00%
Mydecine Innovations Group Inc. の最新の財務報告と株価によると、現在の営業利益率(TTM)は 0.00% です。2026 年末時点では 0.00% でした。
Mydecine Innovations Group Inc. の営業利益率の履歴(2026 から 2026)
各年末の営業利益率
営業利益率 変化
提供された日付のデータは十分ではありません。
同業他社の営業利益率
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。